Gold Cross appoints Brand and Product Manager

Commencing 22 November, Bhavika Mistry has been appointed to the position of brand and product manager at Gold Cross,

The role will oversee the Glucojel range of products and will include the primary responsibility for relationship management of Gold Cross endorsed product partners.

Ms Mistry brings more than nine years of marketing experience with a history of working in logistics, pharmaceuticals, and healthcare industries across Australia and New Zealand.

Before making the move to Melbourne three years ago, her previous experience included working for ProPharma, a division of EBOS Healthcare and Symbion, a wholesaler and distributor to community pharmacies across New Zealand.

Previously Ms Mistry also held a trade marketing management role, where her core focus was to accelerate growth across over-the-counter products and to drive product, trade, and promotional initiatives to national pharmacies across New Zealand.

After making the move to Melbourne, she joined a social enterprise and a national distributor and retailer of healthcare products in Australia.

She held a management role that encompassed managing partnership supplier relationships and promotional initiatives across a large portfolio of products and brands within both B2B and B2C markets.

She brings extensive experience in marketing, product and brand management in the distributor/retailer sectors having worked in both healthcare and pharmacy.

Her key strengths include developing and managing strategic supplier relationships, implementing product strategies, and leading product and promotional marketing initiatives that have contributed to successful growth within both B2B and B2C markets.

Ms Mistry says she is excited to join the Pharmacy Guild and Gold Cross family and looks forward to adding a little magic and building on the continued success Glucojel has had for the last 80 years.


Must Read

Calls for preventative mental health measures

More Australians are prescribed medication for mental illness now compared to 2012 (when records began), costing the nation $566 million in subsidised prescriptions. This is...